Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Enliven Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
19
32.2
38.4
31
64.6
80.8
85.9
General and administrative
5.11
9.54
13
7.77
19
23.8
33.8
Operating expenses
24.1
41.7
51.4
38.8
83.5
105
120
Operating income
-24.1
-41.7
-51.4
-38.8
-83.5
-105
-120
Other non-operating income
0.65
0.34
0.06
1.13
11.9
15.5
16
Pre-tax income
-51.4
1.58
Income tax
0
0
0.23
0
Net income
-23.5
-41.4
-51.4
-37.7
-71.6
-89
-104
EBITDA
-24.1
-41.6
-51.3
-38.6
-83.2
-104
-119
EPS, basic
-33.40
-3.53
-2.37
-12.05
-2.01
-1.89
-1.83
EPS, diluted
-33.40
-3.53
-2.37
-12.05
-2.01
-1.89
-1.83
Shares, basic (weighted)
0.7
13.9
21.7
3.12
35.5
47.1
56.7
Shares, diluted (weighted)
0.7
13.9
21.7
3.12
35.5
47.1
56.7
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
4.94
47.7
48.3
75.5
100
124
98.9
Short-term investments
24
40.5
42
0
153
189
364
Other current assets
1.72
2.18
2.42
2.22
2.95
4.63
12.3
Total current assets
30.6
90.4
92.7
77.8
266
318
475
Property, plant and equipment
0.44
0.35
0.25
0.89
0.74
0.46
0.03
Lease right-of-use assets
0.53
0.63
0.32
0
0.38
Long-term investments
0
Other non-current assets
2.23
0.09
0.18
0
4.09
7.18
0.66
Total assets
33.3
90.8
93.6
83.3
272
326
476
Accounts payable
1.66
1.97
2.36
3.44
0.53
1.34
2.16
Accrued liabilities
2.54
4.28
4.6
1.68
Total current liabilities
4.2
6.25
7.21
9.72
25.9
15.9
16.6
Lease liabilities
0.41
0
0
Other non-current liabilities
0.66
0.07
0
0
Total liabilities
4.38
6.41
7.62
10.4
26
15.9
16.6
Paid-in capital
5.87
181
234
6.04
400
553
806
Retained earnings
-54.8
-96.1
-147
-82.9
-154
-243
-347
Other comprehensive income
0.03
0
-0.02
0
0.14
0.06
0.33
Shareholders' equity
-48.8
84.4
-42.9
-76.8
246
310
460
Total equity
-48.8
84.4
-42.9
-76.8
246
310
460
Total liabilities and equity
33.3
90.8
93.6
83.3
272
326
476
Shares outstanding
0.7
17.5
26.3
3.57
41.3
48.9
59.4
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23.5
-41.4
-51.4
-37.7
-71.6
-89
-104
Depreciation and amortization
0.03
0.1
0.1
0.2
0.3
0.3
0.3
Stock-based compensation
0.9
2.23
3.85
3.19
12.9
20.2
34
Change in payables
0.75
0.31
0.39
0.41
-2.25
0.81
0.82
Cash from operations
-21.9
-37.4
-46.8
-32.1
-61.3
-73.2
-70.3
Capital expenditures
-0.14
-0.02
-0.01
-0.61
-0.15
-0.04
-0.16
Purchases of investments
-23.9
-64.2
-47.6
0
-268
-351
-447
Sales and maturities of investments
0
120
314
273
Cash from investing
-24.1
-16.7
-1.63
-0.61
-148
-36
-174
Stock issued
1.02
0.86
0
161
0
2.3
Cash from financing
43.6
96.9
49.1
-1.8
234
133
219
Net change in cash
-2.36
42.8
0.7
-34.5
24.6
24
-25.3
Free cash flow
-22
-37.4
-46.8
-32.7
-61.4
-73.2
-70.5
Income taxes paid
0
0.21
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $44.75 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-11.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-11.6%
Net income / average total assets.
Return on invested capital (ROIC)
-12.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
48.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
40.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
46.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
78.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
39.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
20.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
162.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
32.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
64.1x
Current assets / current liabilities.
Quick ratio
63.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
63.2x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.01
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.01
Cash from operations / diluted weighted shares.
Book value per share
$12.22
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
3.66x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.66x
Market cap / tangible book value, when positive.
FCF yield
-2.0%
Free cash flow / market cap.
Earnings yield
-3.2%
Net income / market cap (the inverse of P/E).
Was Enliven Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $103.7M.
How much free cash flow did Enliven Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $70.3M minus capital expenditures of $158.0K left free cash flow of -$70.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.